Lead Product(s) : AL001
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : AL001
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Massachusetts General Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AL001
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 05, 2022
Lead Product(s) : AL001
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase 2 Study to Evaluate AL001 in C9orf72-Associated ALS
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Amyotrophic Lateral Sclerosis.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 22, 2021
A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3)
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 05, 2020
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
June 17, 2019
Details : AL001 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Frontotemporal Dementia.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 17, 2018